Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX | Scientific Reports
The current treatment paradigm for patients with metastatic colorectal... | Download Scientific Diagram
Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis | Bentham Science
Biomedicines | Free Full-Text | Identifying Novel Actionable Targets in Colon Cancer
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. | Semantic Scholar
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Promising results for a new bowel cancer treatment
The Trouble With KRAS - Cancer Commons
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis - The Lancet Oncology
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin‑ or irinotecan‑based treatment
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients | Nature Communications
Can KRAS Positive Colorectal and Lung Cancer Finally be Targeted? - CancerConnect
Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients - Ye Yuan, Yingting Liu, Ye Wu, Junling Zhang, Chunti Shen, Feng Zhang, Changping Wu, Wenwei Hu, 2021
JCI Insight - Targeting the undruggable oncogenic KRAS: the dawn of hope
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer | Pharmacogenomics
KRAS-Targeted Therapy Doubles as Component of Immunotherapy - NCI
Life | Free Full-Text | Integrated Decision-Making in the Treatment of Colon -Rectal Cancer: The Case of KRAS-Mutated Tumors
Sotorasib shows activity in advanced colorectal cancer with KRAS G12C mutation
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers - ScienceDirect
Identification of actionable alterations in colorectal cancer are leading to the development of novel treatment strategies - Mayo Clinic
